Abstract
To develop a new therapeutic strategy for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancers, we evaluated the feasibility and efficacy of irinotecan and gemcitabine combination chemotherapy. Patients with taxane/platinum-resistant/refractory cancer received escalating doses of irinotecan and gemcitabine (level 1: 80 and 800 mg/m2, respectively; level 2: 100 and 1000 mg/m2) on days 1 and 8 on a 21-day cycle. Genotyping for UGT1A1*6 and *28 polymorphisms was performed for possible adverse irinotecan sensitivity. A total of 35 patients were enrolled. The recommended dose was defined as 100 mg/m2 irinotecan and 1000 mg/m2 gemcitabine (level 2). The observed common grade 3/4 toxicities were neutropenia (60%), anemia (17.1%), diarrhea (8.6%), thrombocytopenia (5.7%) and nausea (5.7%). Groups homozygous for UGT1A1*6 or *28 were associated with grade 3/4 neutropenia and diarrhea. Objective responses were 20%, including one complete response and six partial responses. In 29 patients treated with the recommended dose, the median progression-free survival and overall survival were 3.8 months (95% CI 2.1-6.0 months) and 17.4 months (95% CI 9.9-21.9 months), respectively, while the 1-year survival rate was 58.6%. C...Continue Reading
References
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Caio Max S Rocha LimaMark R Green
Feb 25, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G P StathopoulosUNKNOWN Greek Cooperative Group for Pancreatic Cancer
Mar 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Federico InnocentiMark J Ratain
Jun 26, 2004·Oncology·Sofia AgelakiUNKNOWN Lung Cancer Subgroup, Hellenic Oncology Research Group
Sep 1, 2005·Cancer·John D HainsworthF Anthony Greco
Nov 22, 2005·Gynecologic Oncology·Koji MatsumotoYasuhiro Fujiwara
Apr 26, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ji-Youn HanJin Soo Lee
Jul 28, 2006·Japanese Journal of Clinical Oncology·Fumiyoshi OhyanagiMakoto Nishio
Sep 30, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter J O'Dwyer, Robert B Catalano
Jun 15, 2007·Pharmacogenetics and Genomics·Hironobu MinamiNagahiro Saijo
Jun 30, 2007·Japanese Journal of Clinical Oncology·Hiroshi TakataniUNKNOWN Nagasaki Thoracic Oncology Group
Jul 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David G MutchAngeles Alvarez Secord
May 30, 2008·Molecular Pharmacology·Marina Gálvez-PeraltaScott H Kaufmann
Oct 1, 2008·Cancer·Stacy MoulderDan Sullivan
Mar 12, 2009·Gynecologic Oncology·Muneaki ShimadaTsunehisa Kaku
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew H KulkeRobert J Mayer
Sep 8, 2010·Expert Opinion on Investigational Drugs·Koji MatsuoAnil K Sood
Dec 14, 2011·Gynecologic Oncology·Marcela G del CarmenJohn O Schorge
Dec 14, 2011·International Journal of Clinical Oncology·Kiyoshi YoshinoTadashi Kimura
Feb 9, 2013·International Journal of Clinical Oncology·Hiroaki KajiyamaFumitaka Kikkawa
Oct 4, 2013·Journal of Human Genetics·Akira HirasawaDaisuke Aoki
Mar 19, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Pujade-LauraineIsabelle Ray-Coquard
Feb 11, 2016·Asia-Pacific Journal of Clinical Oncology·Masashi TakanoYuh Sakata